Shrinkage paradox in intraductal papillary mucinous neoplasms is associated with higher concomitant pancreatic cancer risk
By
Hideyuki Fukui
Teppei Yoshioka
Katsuhiko Sato
Yuki Makino
Hiromitsu Onishi
Atsushi Nakamoto
Takashi Ota
Toru Honda
Feier Ding
Yukihiro Enchi
Daisaku Yamada
Yasunari Fukuda
Hidetoshi Eguchi
Takahiro Kodama
Noriyuki Tomiyama
July 10, 2026
Clinical Scorecard: Association of Size Reduction in Intraductal Papillary Mucinous Neoplasms with Increased Risk of Concurrent Pancreatic Cancer
At a Glance
Category Detail
Condition Intraductal Papillary Mucinous Neoplasms (IPMNs) Key Mechanisms Cyst size change as a risk stratification tool for pancreatic cancer. Target Population Patients with pancreatic cystic lesions, specifically IPMNs. Care Setting Surveillance and management of pancreatic cystic lesions.
Key Highlights
Cyst shrinkage may indicate increased risk of concomitant pancreatic ductal adenocarcinoma (PDAC). Previous studies suggested cyst shrinkage was a reassuring finding. 30-50% of pancreatic cancers detected during IPMN surveillance are concomitant cancers. Guideline-Based Recommendations
Diagnosis
IPMN diagnosis requires imaging features consistent with multilocular cystic lesions. Management
Surveillance strategies have evolved through international consensus guidelines, including the 2024 Kyoto guidelines. Monitoring & Follow-up
Cyst size change is central to risk stratification for surveillance. Risks
Cyst shrinkage may reflect underlying field cancerization and increased PDAC risk. Patient & Prescribing Data
Patients with presumed IPMN undergoing surveillance.
Cyst size change should be carefully monitored to assess cancer risk.
Clinical Best Practices
Utilize imaging protocols for accurate cyst size measurement. Follow guidelines for surveillance intervals based on cyst size. Related Resources & Content
